BeiGene Says It Will Present New Data From SEQUOIA Study Evaluating BRUKINSA Plus Venetoclax In High-Risk First-Line CLL/SLL At EHA2024, Preliminary Data Suggests Efficacy And Tolerability
Portfolio Pulse from Benzinga Newsdesk
BeiGene announced new data from the SEQUOIA study evaluating BRUKINSA plus venetoclax in high-risk first-line CLL/SLL at EHA2024. Preliminary data suggests high efficacy and tolerability.
June 14, 2024 | 10:04 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BeiGene presented new data from the SEQUOIA study at EHA2024, showing high efficacy and tolerability of BRUKINSA plus venetoclax in high-risk first-line CLL/SLL patients.
The presentation of new data showing high efficacy and tolerability of BRUKINSA plus venetoclax in high-risk first-line CLL/SLL patients is likely to positively impact BeiGene's stock price. The 100% ORR and 48% CR/CRi rates are particularly promising, indicating strong potential for the treatment combination.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100